A Score for Predicting Paroxysmal Atrial Fibrillation in Acute Stroke Patients: iPAB Score

详细信息    查看全文

• 作者：Kotaro Yoshioka ; MD^&lowast ; ; ^&dagger ; ; ^{kotanuro@tmd.ac.jp" class="auth_mail" title="E-mail the corresponding author} ; Kosuke Watanabe ; MD^&dagger ; ; Satoshi Zeniya ; MD^&Dagger ; ; Yoko Ito ; MD^&Dagger ; ; Masaki Hizume ; MD ; PhD^&dagger ; ; Toshiro Kanazawa ; MD ; PhD^&dagger ; ; Makoto Tomita ; PhD^§ ; ; Satoru Ishibashi ; MD ; PhD^&lowast ; ; Hirotomo Miake ; MD ; PhD^&Dagger ; ; Hiroaki Tanaka ; MD ; PhD^&dagger ; ; Takanori Yokota ; MD ; PhD^&lowast ; ; Hidehiro Mizusawa ; MD ; PhD^&lowast ;
• 关键词：Acute ischemic stroke ; paroxysmal atrial fibrillation ; cardioembolism ; brain natriuretic peptide
• 刊名：Journal of Stroke and Cerebrovascular Diseases
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：24
• 期：10
• 页码：2263-2269
• 全文大小：310 K

文摘

Detection of paroxysmal atrial fibrillation (PAF) after a stroke is challenging. The purpose of this study was to develop a clinical score to predict PAF in a cohort of acute ischemic stroke patients prospectively and to validate it in an independent cohort.

Methods

Consecutive acute ischemic stroke patients without permanent atrial fibrillation were enrolled in a derivation sample (n = 294) or a validation sample (n = 155). We developed a score for predicting PAF by independent risk factors derived from a logistic regression analysis of the derivation cohort and validated the score in the external cohort.

Results

Multivariate analysis in the derivation cohort identified 3 variables independently associated with PAF. We calculated a score from these variables (history of arrhythmia or antiarrhythmic agent use [yes, 3 points], left atrial dilation [≥40 mm, 1 point], brain natriuretic peptide [BNP, ≥50 pg/mL, 1 point; ≥90 pg/mL, 2 points; ≥150 pg/ml, 3 points], total score, 0-7). The iPAB score (identified by past history of arrhythmia or antiarrhythmic agent use, atrial dilation, and BNP elevation) predicted PAF in the derivation (c statistic, .90) and validation (.94) cohorts at levels statistically superior to other biomarkers and clinical scores. For a total score 2 or more, the sensitivity and specificity were 93% and 71%, respectively. For a total score of 4 or more, the corresponding values were 60% and 95%.

Conclusions

Our prospective study suggests that this simple risk score superior to other scores help clinicians predict PAF or identify good candidates for further evaluation to detect PAF.